learn PP405
mitochondrial pyruvate carrier (MPC) inhibitor by Pelage in early trials
Search
for
Did you mean Pseudopelade of Brocq?
Learn
5 / 801 resultslearn capilia longa
learn platycladus orientalis
learn Pronalen Fibro-Actif
learn SCUBE3
a signaling molecule from dermal papilla cells being actively researched
Research
5 / 393 resultsresearch Importancia de la pseudopelada de Brocq en la práctica de la medicina estética capilar
La detección temprana y precisa de la pseudopelada de Brocq es crucial para detener su progresión.
research Alopecias cicatriciais primárias: revisão de achados histopatológicos de 37 pacientes do Departamento de Dermatologia do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo no período de 2000 a 2005
Accurate diagnosis of cicatricial alopecias requires thorough scalp examination and multiple biopsy techniques.
research A Systematic Review of the Outcome of Hair Transplantation in Primary Scarring Alopecia
Hair transplantation may work for some types of scarring alopecia, but results vary and more research is needed.
research Pseudopelade of Brocq: a clinico-therapeutic challenge!
Pseudopelade of Brocq is hard to diagnose and treat, with limited effective options.
research Pseudopelade of Brocq in beard area
Pseudopelade can affect both the scalp and beard, causing hair loss.
Community Join
5 / 1000+ results
community If You Have DUPA, PLEASE READ THIS: Everyone Should Be Scalp Biopsied
Scalp biopsies are crucial for diagnosing hair loss conditions like Diffuse Unpatterned Alopecia (DUPA) and retrograde hair loss, as treatments like finasteride and dutasteride may not be effective if other conditions are present. Combining PPAR-GAMMA agonists with retinoids could improve treatments for conditions like Lichen Planopilaris.
community Pelage Recruiting Now for Phase 2
Pelage is recruiting for phase 2 trials, showing promise for treating bald regions. The discussion highlights its potential effectiveness based on its mechanism of action.
community Quote from Pelage (PP-405) Spokesperson...
Pelage is developing a topical hair follicle stem cell therapy, PP405, for non-scarring alopecias like androgenetic alopecia, with Phase III trials planned and a potential market launch by 2027. The treatment may not require continuous use after initial regrowth.
community Pelage Pharmaceuticals’ PP405 and its Impact on Follicular Regeneration to be Presented at the American Academy of Dermatology (AAD) Annual Meeting 2026 28th march
Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.
community Pelage Pharmaceuticals Announces Positive Phase 2a Clinical Trial Results for PP405 in Regenerative Hair Loss Therapy
Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.